Trials / Conditions / Relapsed and Refractory
Relapsed and Refractory
6 registered clinical trials studyying Relapsed and Refractory — 3 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesion NCT07198230 | Ting YANG | — |
| Recruiting | Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL NCT06651853 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Unknown | Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurren NCT04626908 | He Huang | Phase 1 / Phase 2 |
| Recruiting | A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies NCT04283006 | He Huang | EARLY_Phase 1 |
| Completed | Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma NCT03376958 | Zhengzhou University | Phase 4 |
| Terminated | Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractor NCT02282358 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |